Gpi — Investor Presentation 2020

Aug 4, 2020

INVESTOR PRESENTATION AUGUST 2020

The context Healthcare

HEALTHCARE: A PIVOTAL MARKET

A segment that can impact a country's economic development, the keeping of public accounts and its very social cohesion

AN EVOLVING MARKET

• demographic ageing and increased life expectancy
• increased health costs (chronic)
• shortage of healthcare staff (doctors) and resources

INCREASED DEMAND FOR CARE

THE CHALLENGE: to make the health systems sustainable, limiting spending and improving quality of service

OPPORTUNITIES: ORGANISATIONAL and TECHNOLOGICAL RENEWAL (digital health care)

Rethinking the organisational models and processes used by the health authorities

Your Global Partner for a Better Future

We develop software, technologies and services to help the health care providers to innovate the models of care, assistance and prevention, optimizing processes and containing costs

A partnership to make health systems sustainable and help improve people's health and well -being

International footprint

History of Growth

30 years of experience, management team with a track record of internal growth and M&As

solutions used by more than 2,200 customers in more than 60 countries

1st player in Italy: services granting access to care

3rd player in Italy: software solutions for healthcare and social systems

Uniqueness

Leadership

integrated software, technology and service solutions to optimise the clinical, care, administrative and social processes.

Quality of life

our work helps improve the quality of life

3

Strategic Business Areas

TECHNOLOGIES 50.6%

Pay 2.8 Automation 4.8 ICT 4.9 Software 38.1

SERVICES 49.4% Care

Note: % revenues for SBA out of total revenues referring to FY 2018

Software

main SBAs

87.5% of total revenue

• health social care
• blood transfusion & tissue bank
• health administration
• data analytics
• other
• BPO health care administrative svc. (AtC,..)
• telemedicine
• other
• Automation
• automated pharmacy warehouse
• automated hospital pharmacy supply chain

other SBAs

12.5 % of total revenue

ICT

Pay

Care

• HW & SW on-site / on-line maintenance and aassistance
• on-site / on-line system services
• e-payment and e-mandate solutions
• electronic storage

GPI in figures

Net profit €M

EBITDA €M *

Staff 2017 2018 2019

A history of steady growth

• +18.3% Vs 2018 ²⁰¹³ Orizzonte fund providing equity financing - First minibond issued.
• ²⁰¹⁶ merger between GPI and the SPAC CFP1. Start of trading in the stock market AIM Italia.
• ²⁰¹⁸ graduated from AIM to MTA main market of Borsa Italiana.

• ^>75 mln M&A deals

*2017 and 2018 EBITDA, net of extraordinary costs; 2019 EBITDA includes the effects of IFRS 16

Gpi vs Covid-19

• Permanent activity supporting the NHS also during the lockdown
• Immediate activation of actions to protect the health of employees, collaborators, suppliers, partners and customers
• Reporting a slowdown of the ordinary health care activities and an increase of extraordinary activities
• Orders confirmed + increased demand for innovative solutions e.g.:

TELEMEDICINE: INTEGRATED ECOSYSTEM OF SOFTWARE SOLUTIONS, MOBILE and WEARABLE DEVICES, OPERATIONS CENTRE SERVICES FOR THE TECHNOLOGY RELATED ASSISTANCE, THE MONITORING OF CLINICAL PARAMETERS AND THE HOME CARE FOR PATIENTS

7

* H-pub: public healthcare customers; H-Pri: private healthcare customers, NH-Pub: public non-healthcare customers; NH-Pri: private non-healthcare customers

Segmentation

Focus on SBA software

Adj. revenue €M EBITDA €M

Supply lines

Tenders win ratio**

• 35%

Revenue predictivity

• 50%

Customer retention

• 92%

Average contract term

• 1-3 years

Average value of tenders acquired

• 6-7 mln/€ year

Competitive position

• 3rd player IT

**Win Ratio as a % of wins to n° of bids. Conversion Win Ratio 6.8% (won contracts value to tenders value 2017- 2019)

Tenders win ratio**

• 40%

Revenue predictivity

• 95%

Customer retention

• 97%

Average contract term

• 4-6 years

Average value of tenders acquired

• 10-15 mln/€ year Competitive position
• 1st operator IT

** Win Ratio as a % of wins to n° of bids. Conversion Win Ratio 16.4% (won contracts value to tenders value 2017- 2019)

* 2018 EBITDA adjusted by extraordinary costs for listing on the MTA

Focus on other SBAs

Automation

Sales of HW for automated warehouses (approx. 87%) and maintenance and service fees (approx. 13%)

• Retail Italy approx. 64%
• Hospital Italy approx. 16%;
• International Hospital & Retail approx. 20%

ICT

Desktop management services fees (approx. 89%) other system services (approx. 11%)

• Healthcare customers approx. 77%
• Non-healthcare PA approx. 17%
• Other private customers approx. 6%

PAY

Automation ICT Pay

ePayment services (approx. 85%), income from POS rental and related software (approx. 15%)

• Organised distribution approx. 50%;
• PAL approx. 23%
• Suppliers of POS-based services approx. 17%
• System integrator approx. 10%

The customers

+2,200 Public and private customers

GPI worldwide

ITALY > 40 branches

SOLUTIONS WORLDWIDE > 60 countries

Overview and main results FY2019

Highlights

• Region of Lazio contract start up 18 lots and Regional Contact Centre: €72 M in 2 years + 1-year extension (Care: CUP) 6 million more citizens reached
• Award of tender for the Region of Veneto: €79 M in 5 + 2 years €27.5 M GPI share (Software: SIO) 8 thousand beds
• X.X XX.X XX.X • Award of 4 tenders in the Region of Marche: €4 M GPI share (Software: FSE, CUP, SISTE, DOC) 5 thousand beds
• Issue of €30 M debenture several underwriters, supported by Cassa Depositi e Prestiti (Deposits and Loans Fund) as anchor invest

M&As

• Haemonetics (assets): U.S. global company listed on the NYSE (Blood Bank) | 11,3 M \$ Rev. |35% EBITDA | 100 clients USA (May 2020)
• Medinfo Group: 3 companies France, Tunisia, Chile (Blood Bank) | 3,9 M€ Rev. | 33% EBITDA| 60 clients NHS UK, Army France and Belgium (May 2020)
• Oslo ( Management Reporting System, Big Data & Analytics) | 4,3 M€ Rev. | 30,2% EBITDA (April 2020)
• Guyot Walser Informatique (Blood Bank) 360 healthcare facilities in France (Nov. 2019)
• Accura (Chronic patient management) and Business Process Engineering (Data Protection) In Italy

Export + 16.4%: new orders Pharmacy Warehouse Automation (> €2 M): Austria, China, Qatar, Saudi Arabia, Switzerland, Hungary, Ireland

Significant growth in 2019

Revenue €240.9 M, +18.3% thanks

to the contribution made by the SBAs:

• Care +35.0%
• Other +21.2%
• SW +1.2%

X.X 2019 characterised by

• XX.X XX.X • 3 acquisitions
• 2 NewCos
• Incorporation of 1 subsidiary

EBITDA: €32.2 M, 14.4% of adj. revenue

Net profit: €9.8 M +3.1%

Revenues +18.3%, Net profit +3.1%	€M	2019	2018
Revenue €240.9 M, +18.3% thanks	Revenue and other income	240.9	203.7
to the contribution made by the SBAs: • Care +35.0%	Adj. revenue (1)	223.3	192.9
• Other +21.2% • SW +1.2%	EBITDA	32.2	28.6 (2)
X.X X.X characterised by 2019	EBITDA % of adj. revenue	14.4%	14.8%
XX.X XX.X • 3 acquisitions • 2 NewCos	Pre-tax profit	12.8	12.8
• Incorporation of 1 subsidiary	Net profit (loss)	9.8	9.5

(1) Net of Temporary grouping of companies (RTI) (2) Net of extraordinary costs for listing on the MTA

A3.1 CERVED Rating confirmed A- S&P |A3 Moody's | A-1 Fitch

Net working capital

€91.3 M (€75.6 M in 2018):

• increase due to growth in revenues and the acquisition of significant orders at year end; accordingly, trade payables also rise (€37.8 M vs €32.2 M)
• X.X • product warehouse: increase connected above all with SBA Automation (€4.8 M vs €3.9 M)

XX.X XX.X Shareholders' equity

€72.1 M (€68.6 M in 2018):

• 2018 dividend payment
• FY 2019 profit
• purchase of treasury shares

Net financial position

€82.8 M (€69.2 M in 2018 - including the effect of IFRS 16)

Investments: M&As €1.8 M | R&D €7.1 M

€M	2019	2018
Net working capital	91.3	75.6
Non-current assets	119.4 (1)	105.2
Other operating assets/(liabilities)	(55.8)	(50.7)
NET INVESTED CAPITAL	154.9	130.1
Shareholders' equity	72.1	68.6
Net financial position	82.8	61.5 (2)
TOTAL SOURCES	154.9	130.1

(1) Includes €11.8 M due to the IFRS 16 effect (2) Net of €7.7 M due to the IFRS 16 effect

Target market and competitive environment

Market Analysis Software Market value

value of the global 2018 Healthcare IT software + services market

47 % North America	CAGR 18 –	22: 6.1%
28 % Western Europe	CAGR 18 –	22: 5.4%
10% Mature Asia/Pacific	CAGR 18 –	22: 4.3%
5 % Latin America	CAGR 18 –	22: 5.3%
4 % Greater China	CAGR 18 –	22: 13.3%

LAGR 18 - 22. 0.170
$CAGR$ 18 - 22: 5.4%
CAGR $18 - 22$ : 4.3%
$CAGR$ 18 – 22: 5.3%
$CAGR$ 18 – 22: 13.3%	II S

|| Source: Gartner (2019)

value of the Italian 2018 Healthcare IT software + services market

1.4% of the global market CAGR 18 – 22: 3.5%

|| Source: Gartner (2019)

€1.7 bn HealthCare IT market €1.1 bn HealthCare IT software + services market || Source: Netics (2019)

Market Analysis Software Top market players

Company	Brief description	Focus on healthcare	Ranking
	ICT solutions and related services for public and private healthcare providers.		1st
	ICT solutions for the segments: finance, industry, telco&utilities and PA.	Through dedicated healthcare division	2nd
	ICT solutions, administrative and social-healthcare services for public and private healthcare providers.		3rd
	Software for hospital processes, orders and risk management Group reply part.		4th
	Digital transformation & ICT services for industries, energy, aerospace, healthcare, PA, etc.	Through dedicated healthcare division	5th

Market Analysis Care Market value & players

€155 m

Italian market value of administrative services (2017)

value underestimated insofar as, at present, part of the market is still insourced.

> 28 M citizens reached

Company	Brief description	Ranking
	ICT solutions, administrative and social-healthcare services for public and private healthcare providers.	1st
	Maintenance services for medical devices, operative in 17 different countries.	N/A
	BPO services (e.g. cleaning, security, logistics and healthcare services).	N/A
	Local supplier of services for healthcare and the educational segment, operates in the Region of Veneto.	N/A
	Local supplier of services for healthcare , operates in the Region of Lazio.	N/A

Strategic intentions 2020-2024

Strategic-corporate intentions 2020 - 2024

EVER MORE GLOBAL 01 GROWTH IN PRIVATE HEALTH CARE ITALY HEALTH CARE SW MARKET LEADERSHIP from PARTNER from PRODUCTS/ SERVICES to INTEGRATED SOLUTIONS 02 03 04 05 Strong increase over the BP period Geographical doubling up of the segment % weight Major regional and national tenders M&As Focus of R&D on all SBAs. Greater integration of services | SW | technologies to respond to the evolution of healthcare models and the healthcare demand.

PROVIDER to

areas of growth: DACH, Russia, China, Middle East and America

Machine Learning and on the digital transformation

Multi-business nature with the contribution of

23

Strategic intentions SBA

01.

MARKET POSITIONING

consolidation of the market position (up-selling and cross-selling), continuous participation in major tenders and strategic partnerships.

02.

GLOBALISATION/TARGET SHIFTING

increase in the percentage share of turnover for the ASA referring to international customers: the target value is 20%.

03.

PRODUCTS PORTFOLIO

harmonisation of the products portfolio, review of the production process to increase productivity and product quality, innovation and technological evolution of the platforms.

Software

DEVELOPMENT DRIVERS

• Average retention ('17-'19) 91%
• Revenue predictivity 50%
• Up/cross selling 2.5%
• Tenders/year €6-7 M

Strategic intentions SBA

CONSOLIDATION OF THE COMPETITIVE POSITIONING

consolidate the market share on the H-PUB target on a national level and the current territorial presence (approx. 50% of the domestic market) through:

• continuous participation in important tenders,
• direct contract acquisition,
• extension of the supply contracts stipulated.

02.

DEVELOPMENT OF THE PRIVATE HEALTHCARE MARKET

develop, define and market the portfolio of new services towards the private H-PRI target group (private clinics, COT, nursing homes, etc.) and to manage chronic patients.

03.

INFRASTRUCTURAL EVOLUTION

technologically evolve the infrastructure in support of services to foster a multichannel approach in access (voice systems, apps, social engagement) and introduce artificial intelligence algorithms to automate certain reception services and reduce the operator's workload.

TECHNOLOGICAL AND PROCESS EVOLUTION

increase efficiency in the supply of contact centre services through the introduction of a technological platform to support HR planning and programming.

Care

DEVELOPMENT DRIVERS

• Average retention '17-19 97%
• Revenue predictivity range 98%-45%
• Tenders/year €10-15M

Strategic intentions Other SBAs

AUTOMATION

PRODUCT AND VALUE PROPOSITION INNOVATION THROUGH R&D OPERATIONS develop new technological solutions (e.g. automated basket/cabinet system for medical devices/cart kit engineering, etc.) and enter new segments (e.g. evolved self-service type solutions and vending machines for the pharmaceutical area, etc.). RETAIL MARKET DEVELOPMENT

enter the market of the major pharmacy chains (capital companies) both for automation and furnishing. Crossselling of the Warehouses and Pharmacy Design Studio range.

ICT

STRATEGIC PARTNERSHIPS FOR NATIONAL TENDERS

development of strategic partnerships with the market's big players (TIM, FastWeb, etc.)

INNOVATION OF OFFER ON PRIVACY & CYBER SECURITY

new value proposition focussed on privacy & cyber security on PAL target and healthcare

PAY

DEVELOPMENT OF THE PUBLIC ADMINISTRATION MARKET

payment services/electronic collection and replacement storage services for the PA

DEVELOPMENT OF SMART PAYMENT FOR VENDING MACHINES

R&D on this topic, partnering dispenser manufacturers and alternative-micro payment systems (e.g. Tinaba, ALIpay, etc.).

DEVELOPMENT OF THE ORGANISED CATERING SEGMENT

improvement of the competitive positioning

DEVELOPMENT DRIVERS

AUTOMATION

• Italy retail (H-PRI, NH-PRI)
• Italy hospital (H-PRI, H-PUB)
• International through Riedl
• International through GPI network

ICT

• Order backlog
• Extension of contracts
• New contracts

PAY

• Large retail and PA (recurring)
• New services PA
• New services Large retail
• Vending machines

2024 economic-financial targets

Equal scope of consolidation as of 31/12/2019

Million Euros

2024 Revenue and EBITDA without M&As

ASA breakdown, equal scope of consolidation as of 31/12/2019

M&A Guidelines

M&A Guidelines

ITALY

1. Product portfolio evolution software/services/territories (€1-10 M revenues)

2. Big players

TARGET

EXPORT

• 1. Structured software companies (€20-30 M revenues)
• 1. Product portfolio evolution

RESOURCES

• BONDS
• TRADITIONAL FINANCING
• WARRANTS
• SHARES/SHARES
• Big players
• Abroad

Investment Attractiveness

Leadership and Uniqueness Growth and Visibility	GPI IN THE STOCK MARKET Bloomberg: GPI:IM 15,909,539 Ordinary Shares (ISIN: IT0005221517) Price: 6.68 € (3 August 2020) Capitalisation: 106.3 M€ (3 August 2020)
Technology and Service	ANALYST COVERAGE – Target price Intermonte SIM (22/04/2020): 10,00 € Banca Akros (02/04/2020): 11.00 €
Evolution of market/client	SHAREHOLDING STRUCTURE
M&A Opportunities	Float 34.91% FM SRL 64,37% Treasury shares

0.72%

IR Contact details

Fabrizio Redavid

Mob. +39 335 1035499 fabrizio.redavid@gpi.it

Lorenzo Giollo

Mob. +39 340 8223333 lorenzo.giollo@gpi.it

Maria Antonietta Pireddu

Via C. Cantù, 1 - 20123 Milan Tel. +39 02 45473883/4 m.pireddu@irtop.com

Via Ragazzi del '99, 13 - 38123 Trento T +39 0461 381515 investor. relations@gpi.it

Disclaimer

The material in this presentation was prepared by GPI S.p.A. ("GPI" or the "Company") without any form of independent verification; it is general, basic information about the current business of GPI as at the date of this presentation. This information is supplied in summary form and is not complete. This presentation is provided for information only and is not an offer or solicitation of an offer of purchase or sale of securities, nor shall there be any sale or purchase of securities in any jurisdiction in which such an offer, solicitation or sale should be illegal before the registration or qualification in accordance with the laws on securities of that jurisdiction. It is intended exclusively by way of a presentation to investors and is provided for information only. This presentation does not contain all information that may be relevant to an investor.

The information contained in this presentation, including the forecast financial information, must not be considered as advice or recommendations to investors or potential investors in connection with the holding, purchase or sale of securities or other products or financial instruments and does not take into account any specific investment targets nor the financial position. Before acting, it is important to consider the adequacy of information in relation to such subjects and, in particular, independent financial advice should be taken. All securities and product transactions or financial instruments entail risks, which include, amongst others, the risk of adverse or unforeseen market, financial or political developments and, in international transactions, the foreign exchange risk. The information contained in this presentation is confidential and is supplied to the user for information only and cannot be reproduced, re-sent or further distributed to anyone else, nor published, entirely or partly, for any purpose. This presentation is only distributed to and intended for: (A) persons in the European Economic Area Member States (excluding the United Kingdom), who are classed as "qualified investors" under Article 2, paragraph 1, letter e) of Directive 2003/71/EC (as amended and complete with any implementing measures applicable in each Member State); (B) in the United Kingdom, professional investment qualified investors coming under Article 19 (5) of the 2005 Order (financial promotion), the Order of Financial Services and markets and/or companies with high shareholders' equity and other persons to whom it can be lawfully disclosed, pursuant to Article 49,

paragraph 2, letters a) to d) of the Order; and (C) other persons to whom this presentation can be legally distributed and disclosed in accordance with applicable laws (all those pursuant to points (A) to (C) above, indicated as "relevant persons").

The information contained in this presentation may include forecasts. Although the Company believes it has a reasonable basis on which to make the forecasts given in this presentation, GPI warns that forecasts are no guarantee of future performance and that the effective operating results, financial conditions and conditions of liquidity and development of the segment in which GPI operates may differ considerably from those effectively achieved or suggested by the declarations given in this presentation or made by the GPI management team. Past performance is also not a reliable indication of future performance.

GPI makes no promise to update or publicly review the forecasts, even if new information is revealed or for any other reason. The information and opinions given in this presentation or in the declarations made by the GPI management team are given as at the date of this presentation or any other date, if indicated, and are subject to change without notice. Do not rely on the information given in this presentation for any purpose. No express or implicit declaration or guarantee is given by GPI, its subsidiaries or the respective consultants, functionaries, employees and agents, as regards the accuracy of information or opinions or for any loss as may derive directly or indirectly from any use of this presentation or its contents. This presentation is not intended for distribution or use by any person or entity that is a citizen or resident of a place, country or other jurisdiction in which such distribution, publication, availability or use may be in conflict with laws or regulations or which would require any registration or licence within such jurisdiction.